Related Experiment Video
Updated: Jan 27, 2026

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
Is Estrogen the Answer for Osteosarcoma?
1Nationwide Children's Hospital, Columbus, Ohio. Ryan.Roberts@nationwidechildrens.org.
Abstract:
Bone biologists have long understood how estrogen drives osteoclasts to make new bone. While evidence hinted that a loss of estrogen signals might also play a role in bone-forming cancers like osteosarcoma, this idea has remained untested. Lillo Osuna and colleagues present data demonstrating widespread epigenetic silencing of estrogen receptor in human osteosarcomas. Exposure to demethylating agents caused reexpression of estrogen receptor, which promoted therapeutic differentiation of these tumors.See related article by Lillo Osuna et al., p. 1054.
Insights
Researchers found that epigenetic silencing of the estrogen receptor (ER) in osteosarcoma (bone cancer) can be reversed. Reactivating ER expression promoted tumor differentiation, offering a potential new therapeutic strategy.
Area of Science:
- Oncology
- Endocrinology
- Epigenetics
Background:
- Estrogen is known to regulate bone formation by affecting osteoclasts.
- A potential role for estrogen signaling loss in osteosarcoma, a bone-forming cancer, has been hypothesized but not investigated.
- Osteosarcoma is a primary bone cancer that affects children and young adults.
Purpose of the Study:
- To investigate the epigenetic status of the estrogen receptor (ER) in human osteosarcomas.
- To determine if reactivating ER expression can influence osteosarcoma tumor behavior.
- To explore potential therapeutic strategies targeting ER in osteosarcoma.
Main Methods:
- Analysis of epigenetic silencing of estrogen receptor (ER) in human osteosarcoma samples.
- Treatment of osteosarcoma cells with demethylating agents to induce ER reexpression.
- Assessment of tumor differentiation following ER reactivation.
Main Results:
- Widespread epigenetic silencing of the estrogen receptor (ER) was observed in human osteosarcomas.
- Exposure to demethylating agents led to the reexpression of ER in these tumors.
- Reexpression of ER promoted the therapeutic differentiation of osteosarcoma cells.
Conclusions:
- Epigenetic silencing of ER is a common feature in osteosarcomas.
- Reactivating ER signaling presents a promising therapeutic avenue for osteosarcoma treatment.
- Targeting ER epigenetic silencing could offer a novel strategy for bone cancer therapy.
Related Concept Videos
The Fluid Mosaic Model
Milgram's Obedience to Authority
Archival Research
Reason and Intuition
Surveys
The Anchoring-and-Adjustment Heuristic

